Matthew Hickman, Professor in
Public Health and Epidemiology at the University of Bristol's School of Social and Community Medicine and lead author of the study, said: «
Scaling up HCV treatment is critical to the prevention of HCV in the population to support and enhance traditional
harm reduction measures — opiate substitution treatment and needle exchange.